23 documents

Read All
07:00 , Sep 21, 1998 |  BC Week In Review  |  Company News

Cytogen cancer, diagnostics/imaging news

CYTO ceased operations at its Cellcor Inc. subsidiary, which was developing its autologous lymphocyte therapy (ALT) to treat metastatic renal cell carcinoma. CYTO had been in discussions concerning either a management buyout or other sale...
Read More
07:00 , Aug 3, 1998 |  BC Week In Review  |  Company News

Cytogen cancer, diagnostics/imaging news

CYTO said that negotiations for the sale of its Cellcor Inc. subsidiary have fallen through and CYTO's board is considering a proposed buyout of Cellcor by its management (see BioCentury, March 30). Cytogen Corp. (CYTO),...
Read More
08:00 , Mar 30, 1998 |  BC Week In Review  |  Company News

Cytogen cancer, diagnostics/imaging news

CYTO said it will halt its autologous lymphocyte therapy (ALT) program, which was under development by CYTO's Cellcor Inc. subsidiary, until a partner for the program can be found. Cellcor completed Phase III trials with...
Read More
08:00 , Jan 26, 1998 |  BC Week In Review  |  Company News

Cytogen management update

Cytogen Corp. (CYTO), Princeton, N.J.   Business: Diagnostics/Imaging   Transition: John Bagalay to interim president and CEO while remaining CFO, replacing Thomas McKearn who relinquished his positions as CYTO's chairman, president and CEO to become...
Read More
08:00 , Jan 26, 1998 |  BC Week In Review  |  Company News

Cytogen board of directors update

Cytogen Corp. (CYTO), Princeton, N.J.   Business: Diagnostics/Imaging   Appointed: William Mills, general partner of The Venture Capital Fund of New England, as chairman, replacing Thomas McKearn who relinquished his positions as CYTO's chairman, president...
Read More
08:00 , Dec 23, 1996 |  BC Week In Review  |  Company News

Cytogen, Neoprobe deal

CYTO's Cellcor subsidiary (Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic colorectal cancer. Cellcor will receive an up front fee and will record contract revenue on a per patient basis....
Read More
07:00 , Jun 10, 1996 |  BC Week In Review  |  Company News

Cytogen, Neoprobe deal

NEOP signed a letter of intent to manufacture its RIGS/ACT activated cell therapy product using the cell processing and development manufacturing facility in Needham, Mass., operated by CYTO's Cellcor subsidiary. NEOP retains exclusive rights to...
Read More
07:00 , Oct 23, 1995 |  BC Week In Review  |  Company News

Cellcor, Cytogen deal

Shareholders of both companies approved CYTO's acquisition of CLTX, and the accompanying subscription offering to CLTX shareholders (see BioCentury June 19). Under the subscription offering, which has been completed, CLTX shareholders of record on Aug....
Read More
07:00 , Sep 25, 1995 |  BC Week In Review  |  Clinical News

Autolymphocyte therapy: To start patient accrual in the fourth quarter under a Treatment IND in patients with stage IV disease who did not participate in the co

CLTX is in the process of merging with CYTOGEN Corp. (Princeton, N.J.) (see page B2). Cellcor Inc. (CLTX), Newton, Mass.   Product: Autolymphocyte therapy (ALT), which uses a patient's own immune cells to treat disease...
Read More
07:00 , Sep 25, 1995 |  BC Week In Review  |  Company News

Cytogen, Cellcor deal

The companies' stockholders will meet on Oct. 16 to address the proposed merger of CLTX into CYTO. CYTO shareholders will be asked to approved the issuance of up to 12 million shares of CYTO common...
Read More